Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.

Pfizer Inc. signed a multi-year agreement to make Gilead Sciences Inc.’s antiviral drug remdesivir in a bid to ramp up supply of the Covid-19 treatment.

One small pharma company is meeting the challenge of COVID-19 by finding new ways to support the practices of its specialist physician customers.

Clinical-stage biopharmaceutical company Zosano Pharma Corporation announced a partnership with EVERSANA, a leading provider of commercial services to the life science industry, to commercialize and distribute Qtrypta in the United States.

Humira

AbbVie Inc. agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting the company’s blockbuster drug Humira, California’s insurance regulator said.

Biogen inked a binding deal to co-develop and co-commercialize Denali Therapeutics’ small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.

A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.

T-knife GmbH, based in Berlin, Germany, closed a €66 million ($78.4 million) Series A round led by Versant Ventures and RA Capital Management.

Virginia launched the first contact tracing app for the novel coronavirus in the United States that uses new technology from Apple Inc. and Alphabet Inc.’s Google.

ARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC.